Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own37.02% Shs Outstand92.70M Perf Week-21.28%
Market Cap669.01M Forward P/E- EPS next Y-4.38 Insider Trans0.00% Shs Float61.24M Perf Month-24.64%
Income- PEG- EPS next Q-1.00 Inst Own68.89% Short Float / Ratio10.21% / 4.38 Perf Quarter-74.63%
Sales- P/S- EPS this Y64.89% Inst Trans- Short Interest6.25M Perf Half Y-60.69%
Book/sh7.53 P/B0.91 EPS next Y40.90% ROA- Target Price30.75 Perf Year-
Cash/sh8.11 P/C0.85 EPS next 5Y- ROE- 52W Range5.77 - 29.88 Perf YTD-70.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.97% Beta-
Dividend %- Quick Ratio11.88 Sales past 5Y0.00% Gross Margin- 52W Low19.24% ATR0.73
Employees51 Current Ratio11.88 Sales Q/Q- Oper. Margin- RSI (14)34.57 Volatility14.11% 8.15%
OptionableYes Debt/Eq0.00 EPS Q/Q-452.98% Profit Margin- Rel Volume0.70 Prev Close6.72
ShortableYes LT Debt/Eq0.00 EarningsNov 07 AMC Payout- Avg Volume1.43M Price6.88
Recom1.40 SMA20-18.08% SMA50-25.83% SMA200-60.58% Volume993,274 Change2.38%
Date Action Analyst Rating Change Price Target Change
Sep-13-23Downgrade Morgan Stanley Overweight → Equal-Weight $19
Sep-05-23Initiated H.C. Wainwright Buy $44
May-30-23Initiated TD Cowen Outperform
May-30-23Initiated Piper Sandler Overweight $68
May-30-23Initiated Morgan Stanley Overweight
May-30-23Initiated Jefferies Buy $31
Nov-30-23 04:30PM
Nov-28-23 05:55PM
Nov-27-23 09:09PM
04:30PM Loading…
Nov-20-23 11:01AM
Nov-16-23 06:42PM
Nov-07-23 05:11PM
Nov-06-23 07:00AM
Oct-31-23 04:30PM
Oct-18-23 09:00PM
Oct-03-23 07:00AM
05:39PM Loading…
Sep-15-23 05:39PM
Sep-11-23 04:05PM
Sep-06-23 07:00AM
Aug-15-23 07:22PM
Aug-14-23 04:05PM
Aug-07-23 04:30PM
Jul-18-23 07:00AM
Jun-15-23 04:05PM
May-09-23 04:10PM
May-05-23 07:08PM
ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Westlake BioPartners Fund II, 10% OwnerMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:16 PM
SEIDENBERG BETH CDirectorMay 09Buy18.001,250,00022,500,0009,790,729May 11 09:13 PM
SEIDENBERG BETH CDirectorMay 09Buy18.0060,0001,080,00060,000May 11 09:13 PM
Gosebruch Henry ODirectorMay 09Buy18.0050,000900,00050,000May 11 09:06 PM
Svoronos DawnDirectorMay 09Buy18.0015,000270,00015,000May 11 09:11 PM
Peloso PaulChief Medical OfficerMay 09Buy18.006,000108,0006,000May 11 08:54 PM
Dier MardiCFO and CBOMay 09Buy18.005,556100,0085,556May 11 08:51 PM
Kim MinaChief Legal & Admin. OfficerMay 09Buy18.005,00090,0005,000May 11 08:58 PM
Becker Daniel J.DirectorMay 09Buy18.003,00054,0003,000May 11 09:02 PM
Dier MardiCFO and CBOMay 09Buy18.001,75031,500875May 11 08:51 PM
Oyston RonaldChief People OfficerMay 09Buy18.001,00018,0001,000May 11 09:00 PM
Oyston RonaldChief People OfficerMay 09Buy18.002646826May 11 09:00 PM